Editas Medicine Inc
NASDAQ:EDIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Mitsubishi UFJ Financial Group Inc
TSE:8306
|
JP |
|
S
|
Shri Gang Industries and Allied Products Ltd
BSE:523309
|
IN |
|
Kawasaki Heavy Industries Ltd
TSE:7012
|
JP |
Editas Medicine Inc
Stock-Based Compensation
Editas Medicine Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Editas Medicine Inc
NASDAQ:EDIT
|
Stock-Based Compensation
$10m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
11%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Stock-Based Compensation
$955m
|
CAGR 3-Years
12%
|
CAGR 5-Years
5%
|
CAGR 10-Years
13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Stock-Based Compensation
$894m
|
CAGR 3-Years
12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Stock-Based Compensation
$494m
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Stock-Based Compensation
$685.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Stock-Based Compensation
$993.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
18%
|
CAGR 10-Years
8%
|
|
Editas Medicine Inc
Glance View
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.
See Also
What is Editas Medicine Inc's Stock-Based Compensation?
Stock-Based Compensation
10m
USD
Based on the financial report for Dec 31, 2025, Editas Medicine Inc's Stock-Based Compensation amounts to 10m USD.
What is Editas Medicine Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
11%
Over the last year, the Stock-Based Compensation growth was -53%. The average annual Stock-Based Compensation growth rates for Editas Medicine Inc have been -30% over the past three years , -15% over the past five years , and 11% over the past ten years .
